| The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study. | |
| | |
MedLine Citation:
|
PMID: 21926432 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: to examine the effect of medications with anticholinergic effects on cognitive impairment and deterioration in Alzheimer's dementia (AD). METHODS: cognitive function was measured at baseline and at 6- and 18-month follow-up using the Mini-Mental State Exam (MMSE), the Severe Impairment Battery (SIB) and the Alzheimer's Disease Assessment Battery, Cognitive subsection (ADAS-COG) in a cohort study of 224 participants with AD. Baseline anticholinergic Burden score (ABS) was measured using the Anticholinergic Burden scale and included all prescribed and over the counter medication. RESULTS: the sample was 224 patients with Alzheimer's dementia and 71.4% were women. Their mean age was 81.0 years [SD 7.4 (range 55-98)]. The mean number of medications taken was 3.6 (SD 2.4) and the mean anticholinergic load was 1.1 (SD 1.4, range 0-7). The total number of drugs taken and anticholinergic load correlated (rho = 0.44; P < 0.01). There were no differences in MMSE and other cognitive functioning at either 6 or 18 months after adjusting for baseline cognitive function, age, gender and use of cholinesterase inhibitors between those with, and those without high anticholinergenic load. CONCLUSIONS: medications with anticholinergic effect in patients with AD were not found to effect deterioration in cognition over the subsequent 18 months. Our study did not support a continuing effect of these medications on people with AD who are established on them. |
| | |
Authors:
|
Chris Fox; Gill Livingston; Ian D Maidment; Simon Coulton; David G Smithard; Malaz Boustani; Cornelius Katona |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-09-18 |
Journal Detail:
|
Title: Age and ageing Volume: 40 ISSN: 1468-2834 ISO Abbreviation: Age Ageing Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-10-21 Completed Date: 2012-03-26 Revised Date: 2012-04-23 |
Medline Journal Info:
|
Nlm Unique ID: 0375655 Medline TA: Age Ageing Country: England |
Other Details:
|
Languages: eng Pagination: 730-5 Citation Subset: IM |
Affiliation:
|
Dementia Research Innovation Group, Norwich School of Medicine, Norwich Research Park, University of East Anglia, UK. chris.fox@uea.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alzheimer Disease / drug therapy*, prevention & control* Cholinergic Antagonists / therapeutic use* Cognition Disorders / prevention & control* Cohort Studies Disease Progression* Dose-Response Relationship, Drug Female Follow-Up Studies Great Britain Humans Longitudinal Studies Male Middle Aged Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Cholinergic Antagonists |
| Comments/Corrections | |
Comment In:
|
J Urol. 2012 Apr;187(4):1356-7
[PMID:
22423930
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endoplasmic reticulum localization of DHHC palmitoyl transferases mediated by lysine-based sorting s...
Next Document: Modelling proteolytic enzymes with support vector machines.